Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICONS: Early Rituximab in Childhood-Onset Idiopathic Nephrotic Syndrome
2020-004982-37Phase 3Active
- Sponsor
- Medical University of Gdańsk
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nephrosis comparing Rituximab arm with Placebo arm (2 arms). Primary endpoint: Relapse-free time. Started Dec 2020; status: active.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2020-004982-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004982-37.